Comparison of adriamycin (NSC-123127) and the combination of 5-fluorouracil (NSC-19893) and cyclophosphamide (NSC-26271) in advanced prostatic cancer: a preliminary report.
A preliminary report on chemotherapy for advanced prostate malignancy is presented. Nine patients have been entered in the study, of which eight are evaluable for tumor response. Of four patients initially treated with adriamycin, only one brief (5-week) objective response was noted in a patient with soft tissue disease. No responses have been seen in four patients treated with the combination of 5-fluorouracil and cyclophosphamide. No responses have been noted in five patients who failed initial treatment and were crossed over to the other treatment. Durg toxicity has been quite acceptable.
D000368:Aged; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use*; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005472:Fluorouracil / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000188:drug therapy*
D004317:Doxorubicin; D003520:Cyclophosphamide; D005472:Fluorouracil